Last updated: 2026-10-15 16:19:40. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Alpha Tau Medical Ltd. (DRTS) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $13.24, with a market capitalisation of $1.27B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3.43 to $15.79. This page covers its latest market performance, valuation, price trends and company information.
$1.27B | |
$13.14 | |
$20.65 | |
$1.75 | |
$13.50 | |
268.30K | |
553.37K | |
-- | |
$15.79 | |
$3.43 | |
-- | |
-- |
Alpha Tau Medical Ltd. (DRTS) is currently trading at $13.24 as of 2026-10-15 16:17:00, down 1.92% ($0.26) from the previous close of $13.50
During today's regular trading session, DRTS has traded between $1.75 and $20.65, with a trading volume of 268.30K shares. The current price is near the middle of today's range.
Over the past seven days, Alpha Tau Medical Ltd. (DRTS) moved from $14.48 to $13.24, representing a decline of 8.56% ($1.24).
The stock traded between $13.11 and $15.02 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 435.17 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 79.4%
DRTS is currently trading at $13.24, placing it 79.4% of the way from its 52-week low of $3.43 to its 52-week high of $15.79. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.
| Employees | 121 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Alpha Tau Medical Ltd. (DRTS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.